<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02268396</url>
  </required_header>
  <id_info>
    <org_study_id>PT003016-00</org_study_id>
    <nct_id>NCT02268396</nct_id>
  </id_info>
  <brief_title>Glycopyrronium and Formoterol Fumarate (GFF) Metered Dose Inhaler (MDI) Dose Indicator Study in Adults With Moderate to Very Severe COPD</brief_title>
  <official_title>An Open-Label, Multi-Center, Dose Indicator Study of Glycopyrronium and Formoterol Fumarate (GFF) Metered Dose Inhaler (MDI) in Adult Subjects With Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pearl Therapeutics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pearl Therapeutics, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an open-label, multi-center study to evaluate the accuracy, reliability and
      functionality of the Glycopyrronium and Formoterol Fumarate (GFF) Metered Dose Inhaler (MDI)
      dose indicator in adult subjects with moderate to very severe COPD over a 4-week Treatment
      Period.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2014</start_date>
  <completion_date type="Actual">May 2015</completion_date>
  <primary_completion_date type="Actual">January 2015</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Dose Indicator Actuation Consistency: Percentage of Devices in Agreement Between CRF-Based Dose Indicator Actuation Count</measure>
    <time_frame>Over the life of the canister/120 puffs - up to 4 weeks</time_frame>
    <description>Dose Indicator Actuation Consistency: Percentage of Devices in Agreement Between CRF-Based Dose Indicator Actuation Count and Subject-Reported Actuation Count at the Last Available Visit: ITT Population</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Devices in Agreement Between eCRF-Based Dose Indicator Actuation Count and Weight-Based Actuation Count at the Last Available Visit</measure>
    <time_frame>Over the life of the canister/120 puffs - up to 4 weeks</time_frame>
    <description>Percentage of devices whose number of actuations counted at the end of the study, using the dose indicator reading, was consistent (±20 actuations) with the number of actuations used as estimated by the change in MDI weight</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Devices in Agreement Between Laboratory-Advanced Dose Indicator Actuation Count and Subject-Reported Actuation Count at the Last Available Visit</measure>
    <time_frame>Over the life of the canister/120 puffs - up to 4 weeks</time_frame>
    <description>Percentage of devices whose number of actuations counted at the end of the study, using the lab-advanced dose indicator reading, was consistent (±20 actuations) with the number of actuations used as reported by the subject</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Devices in Agreement Between Laboratory-advanced Does Indicator Actuation and Weight-based Actuation Count at Last Available Visit.</measure>
    <time_frame>Over the life of the canister/120 puffs - up to 4 weeks</time_frame>
    <description>Percentage of devices whose number of actuations counted at the end of the study, using the dose indicator reading, was consistent (±20 actuations) with the number of actuations used as estimated by the change in MDI weight</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Devices Where the Dose Indicator Actuation Count is &gt;20 Less Than the Subject-reported Actuation Count (Undercount)</measure>
    <time_frame>Over the life of the canister/120 puffs - up to 4 weeks</time_frame>
    <description>Percentage of devices where the dose indicator actuation count is &gt;20 less than the subject-reported actuation count (undercount)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Correct Advances (±2 or ±4 Actuations) of the Dose Indicator Based on Subject-reported Actuation Count</measure>
    <time_frame>Over the life of the canister/120 puffs - up to 4 weeks</time_frame>
    <description>Percentage of Correct Advances (±2 or ±4 Actuations) of the Dose Indicator Based on Subject-reported Actuation Count</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">138</enrollment>
  <condition>COPD</condition>
  <arm_group>
    <arm_group_label>Glycopyrronium and Formoterol Fumarate Metered Dose Inhaler</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Glycopyrronium and Formoterol Fumarate Metered-dose Inhaler (GFF MDI), PT003</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Glycopyrronium and Formoterol Fumarate Metered-dose Inhaler</intervention_name>
    <description>GFF MDI administered as 2 inhalations BID</description>
    <arm_group_label>Glycopyrronium and Formoterol Fumarate Metered Dose Inhaler</arm_group_label>
    <other_name>GFF MDI, PT003</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Give their signed written informed consent to participate.

          -  Are at least 40 years of age and no older than 80 at Visit 1.

          -  A female of non-child bearing potential or child bearing potential, has a negative
             serum pregnancy test, and agrees to approved contraceptive methods.

          -  COPD Diagnosis: Subjects with an established clinical history of COPD as defined by
             the American Thoracic Society(ATS)/European Respiratory Society (ERS).

          -  Current or former smokers with a history of at least 10 pack-years of cigarette
             smoking.

          -  FEV1/FVC ratio of &lt;0.70.

          -  Post-bronchodilator FEV1 must be ≥ 30% and &lt;80% predicted normal value calculated
             using the Third National Health and Nutrition Examination Survey (NHANES III)
             reference equations, and must also be greater than or equal to 750 mL.

          -  Subject is willing and, in the opinion of the Investigator, able to adjust current
             COPD therapy as required by the protocol.

        Exclusion Criteria:

          -  Pregnancy, nursing females or subjects trying to conceive.

          -  Clinically significant neurologic, cardiovascular, hepatic, renal, endocrinologic,
             pulmonary, hematological, psychiatric, or other medical illness that would interfere
             with participation in this study.

          -  Current primary diagnosis of asthma.

          -  History of ECG abnormalities.

          -  Poorly controlled or worsening COPD prior to Screening or during the Screening Period.

          -  Clinically significant bladder neck obstruction or urinary retention.

          -  Male subjects with a trans-urethral resection of prostate (TURP) or full resection of
             the prostate within 6 months prior to Screening.

          -  Cancer that has not been in complete remission for at least five years.

          -  Inadequately treated glaucoma.

          -  History of allergic reaction or hypersensitivity to any component of the formulations
             used in this study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Colin Reisner, MD</last_name>
    <role>Study Director</role>
    <affiliation>Pearl Therapeutics</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Pearl Investigative Site</name>
      <address>
        <city>Clearwater</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pearl Investigative Site</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pearl Investigative Site</name>
      <address>
        <city>Winter Park</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pearl Investigative Site</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pearl Investigative Site</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pearl Investigative Site</name>
      <address>
        <city>Medford</city>
        <state>Oregon</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pearl Investigative Site</name>
      <address>
        <city>Greenville</city>
        <state>South Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pearl Investigative Site</name>
      <address>
        <city>Rock Hill</city>
        <state>South Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pearl Investigative Site</name>
      <address>
        <city>Spartanburg</city>
        <state>South Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pearl Investigative Site</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 15, 2014</study_first_submitted>
  <study_first_submitted_qc>October 15, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 20, 2014</study_first_posted>
  <results_first_submitted>May 23, 2016</results_first_submitted>
  <results_first_submitted_qc>October 31, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">December 23, 2016</results_first_posted>
  <disposition_first_submitted>July 7, 2015</disposition_first_submitted>
  <disposition_first_submitted_qc>July 7, 2015</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">July 30, 2015</disposition_first_posted>
  <last_update_submitted>October 31, 2016</last_update_submitted>
  <last_update_submitted_qc>October 31, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 23, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Formoterol Fumarate</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Conducted at 10 study sites in the United states from November 2014 - January 2015. The entire study period was scheduled to take approximately 6 weeks for each individual subject. The study was anticipated to run for approximately 6 months.</recruitment_details>
      <pre_assignment_details>Study was an open-label, multi center study to evaluate the accuracy, reliability, and functionality of GFF MDI dose indicator in adult subjects with moderate to very severe COPD over a 4-week treatment period.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>GFF MDI (PT003)</title>
          <description>GFF MDI 14.4/9.6 μg</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="138"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="126"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Administrative</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol-Specified Criteria</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>2 Subjects no Day 29 Assessment</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>126 received treatment on Day 1 and 29, 10 prematurely discontinued, 2 with no assessment on Day 29.</population>
      <group_list>
        <group group_id="B1">
          <title>GFF MDI (PT003)</title>
          <description>GFF MDI 14.4/9.6 μg</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="138"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="62.1" spread="8.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="68"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Dose Indicator Actuation Consistency: Percentage of Devices in Agreement Between CRF-Based Dose Indicator Actuation Count</title>
        <description>Dose Indicator Actuation Consistency: Percentage of Devices in Agreement Between CRF-Based Dose Indicator Actuation Count and Subject-Reported Actuation Count at the Last Available Visit: ITT Population</description>
        <time_frame>Over the life of the canister/120 puffs - up to 4 weeks</time_frame>
        <population>ITT Population</population>
        <group_list>
          <group group_id="O1">
            <title>GFF MDI (PT003)</title>
            <description>GFF MDI 14.4/9.6 μg</description>
          </group>
        </group_list>
        <measure>
          <title>Dose Indicator Actuation Consistency: Percentage of Devices in Agreement Between CRF-Based Dose Indicator Actuation Count</title>
          <description>Dose Indicator Actuation Consistency: Percentage of Devices in Agreement Between CRF-Based Dose Indicator Actuation Count and Subject-Reported Actuation Count at the Last Available Visit: ITT Population</description>
          <population>ITT Population</population>
          <units>Percentage</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="137"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="96.4" spread="18.9" lower_limit="0" upper_limit="130"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Devices in Agreement Between eCRF-Based Dose Indicator Actuation Count and Weight-Based Actuation Count at the Last Available Visit</title>
        <description>Percentage of devices whose number of actuations counted at the end of the study, using the dose indicator reading, was consistent (±20 actuations) with the number of actuations used as estimated by the change in MDI weight</description>
        <time_frame>Over the life of the canister/120 puffs - up to 4 weeks</time_frame>
        <population>ITT Population</population>
        <group_list>
          <group group_id="O1">
            <title>GFF MDI (PT003)</title>
            <description>GFF MDI 14.4/9.6 μg</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Devices in Agreement Between eCRF-Based Dose Indicator Actuation Count and Weight-Based Actuation Count at the Last Available Visit</title>
          <description>Percentage of devices whose number of actuations counted at the end of the study, using the dose indicator reading, was consistent (±20 actuations) with the number of actuations used as estimated by the change in MDI weight</description>
          <population>ITT Population</population>
          <units>Percentage of Devices</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="137"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="86.9" spread="19.0" lower_limit="18" upper_limit="130"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Devices in Agreement Between Laboratory-Advanced Dose Indicator Actuation Count and Subject-Reported Actuation Count at the Last Available Visit</title>
        <description>Percentage of devices whose number of actuations counted at the end of the study, using the lab-advanced dose indicator reading, was consistent (±20 actuations) with the number of actuations used as reported by the subject</description>
        <time_frame>Over the life of the canister/120 puffs - up to 4 weeks</time_frame>
        <population>ITT Population</population>
        <group_list>
          <group group_id="O1">
            <title>GFF MDI (PT003)</title>
            <description>GFF MDI 14.4/9.6 μg</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Devices in Agreement Between Laboratory-Advanced Dose Indicator Actuation Count and Subject-Reported Actuation Count at the Last Available Visit</title>
          <description>Percentage of devices whose number of actuations counted at the end of the study, using the lab-advanced dose indicator reading, was consistent (±20 actuations) with the number of actuations used as reported by the subject</description>
          <population>ITT Population</population>
          <units>Percentage of devices</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="132"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="96.2" spread="19.0" lower_limit="0" upper_limit="130"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Devices in Agreement Between Laboratory-advanced Does Indicator Actuation and Weight-based Actuation Count at Last Available Visit.</title>
        <description>Percentage of devices whose number of actuations counted at the end of the study, using the dose indicator reading, was consistent (±20 actuations) with the number of actuations used as estimated by the change in MDI weight</description>
        <time_frame>Over the life of the canister/120 puffs - up to 4 weeks</time_frame>
        <population>ITT Population</population>
        <group_list>
          <group group_id="O1">
            <title>GFF MDI (PT003)</title>
            <description>GFF MDI 14.4/9.6 μg</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Devices in Agreement Between Laboratory-advanced Does Indicator Actuation and Weight-based Actuation Count at Last Available Visit.</title>
          <description>Percentage of devices whose number of actuations counted at the end of the study, using the dose indicator reading, was consistent (±20 actuations) with the number of actuations used as estimated by the change in MDI weight</description>
          <population>ITT Population</population>
          <units>Percentage</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="132"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="75.0" spread="19.0" lower_limit="17" upper_limit="171"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Devices Where the Dose Indicator Actuation Count is &gt;20 Less Than the Subject-reported Actuation Count (Undercount)</title>
        <description>Percentage of devices where the dose indicator actuation count is &gt;20 less than the subject-reported actuation count (undercount)</description>
        <time_frame>Over the life of the canister/120 puffs - up to 4 weeks</time_frame>
        <population>ITT Population</population>
        <group_list>
          <group group_id="O1">
            <title>GFF MDI (PT003)</title>
            <description>GFF MDI 14.4/9.6 μg</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Devices Where the Dose Indicator Actuation Count is &gt;20 Less Than the Subject-reported Actuation Count (Undercount)</title>
          <description>Percentage of devices where the dose indicator actuation count is &gt;20 less than the subject-reported actuation count (undercount)</description>
          <population>ITT Population</population>
          <units>Percentage</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="132"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.9" spread="2.9" lower_limit="17" upper_limit="171"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Correct Advances (±2 or ±4 Actuations) of the Dose Indicator Based on Subject-reported Actuation Count</title>
        <description>Percentage of Correct Advances (±2 or ±4 Actuations) of the Dose Indicator Based on Subject-reported Actuation Count</description>
        <time_frame>Over the life of the canister/120 puffs - up to 4 weeks</time_frame>
        <population>ITT Population</population>
        <group_list>
          <group group_id="O1">
            <title>GFF MDI (PT003)</title>
            <description>GFF MDI 14.4/9.6 μg</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Correct Advances (±2 or ±4 Actuations) of the Dose Indicator Based on Subject-reported Actuation Count</title>
          <description>Percentage of Correct Advances (±2 or ±4 Actuations) of the Dose Indicator Based on Subject-reported Actuation Count</description>
          <population>ITT Population</population>
          <units>Percentage of correct advances</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="132"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Correct within ±2 actuations</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="87.3" lower_limit="17" upper_limit="171"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Correct within ±4 actuations</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="93.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>AEs occurring between when signed consent and randomized reported as SAEs up to 14 days following last dose of study drug. AEs occurring at time of and following first study drug administration were reported and followed until stabilized/resolved.</time_frame>
      <desc>Safety population included all participants who received at least one dose of investigational drug and had safety data available (Note: A subject who used the GFF MDI, but took less than 1 full dose of treatment qualified for this population.)</desc>
      <group_list>
        <group group_id="E1">
          <title>GFF MDI (PT003)</title>
          <description>GFF MDI 14.4/9.6 μg</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="138"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Metastatic Neoplasm</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="138"/>
              </event>
              <event>
                <sub_title>Metastatic Pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="138"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>COPD</sub_title>
                <description>Chronic Obstructive pulmonary disease</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="138"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="138"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>COPD</sub_title>
                <description>Chronic Obstructive Pulmonary disease</description>
                <counts group_id="E1" events="11" subjects_affected="10" subjects_at_risk="138"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Drafts of any and all publications or presentations of this study must be submitted at least 30 days prior to submission for publication or presentation to Pearl Therapeutics for review, approval, and to ensure consistency. Pearl Therapeutics has the right to request appropriate modification to correct facts and to represent its opinions, or the opinions of the publication committee, if these differ with the proposed publication.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Colin Reisner, MD, FCCP, FAAAAI</name_or_title>
      <organization>Pearl Therapeutics Inc</organization>
      <phone>973-975-0320</phone>
      <email>creisner@pearltherapeutics.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

